The diabetic neuropathy drugs market share is expected to increase by USD 2.37 billion from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 12.20%.
This diabetic neuropathy drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers diabetic neuropathy drugs market segmentation by product (calcium channel alpha-2-delta ligand, SNRIs and TCAs, and others) and geography (North America, Europe, Asia, and ROW). The diabetic neuropathy drugs market report also offers information on several market vendors, including Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Grunenthal GmbH, Johnson and Johnson Inc., NeuroBo Pharmaceuticals Inc., Novartis AG, and Pfizer Inc. among others.
What will the Diabetic Neuropathy Drugs Market Size be During the Forecast Period?
Download the Free Report Sample to Unlock the Diabetic Neuropathy Drugs Market Size for the Forecast Period and Other Important Statistics
Diabetic Neuropathy Drugs Market: Key Drivers, Trends, and Challenges
The increasing prevalence of diabetic neuropathy is notably driving the diabetic neuropathy drugs market growth, although factors such as the high cost of treatment may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the diabetic neuropathy drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Diabetic Neuropathy Drugs Market Driver
The increasing prevalence of diabetic neuropathy is one of the key drivers supporting the diabetic neuropathy drugs market growth. Diabetic neuropathy often damages nerves in the feet and legs of an individual. The prevalence of diabetic neuropathy has increased due to the rise in the prevalence of diabetes globally. according to the CDC, in 2021, 50% of people with diabetes had some form of nerve damage. The longer a person has diabetes, the higher is the risk of developing neuropathy. About one-third to one-half of people with diabetes have peripheral neuropathy. About 60%-70% of people with diabetes develop diabetic neuropathy. Thus, such an increase in the number of diabetic neuropathy is driving the market growth.
Key Diabetic Neuropathy Drugs Market Trend
The development of topical patches for the treatment of diabetic neuropathy is another factor supporting the diabetic neuropathy drugs market growth. The traditional approaches for the treatment of neuropathic pain associated with diabetic neuropathy led to many complications, which affected patient compliance. Topical treatments are considered an effective way to treat chronic pain as the current treatments have limited absorption. Also, topical treatments are safer than systemic treatment options. For instance, 5% of topical lidocaine applied as a patch can treat diabetic neuropathy. In May 2009, Qutenza was approved for the treatment of non-diabetic adults with peripheral neuropathy and in September 2015, the license of the drug included diabetic patients as well. Such a rapid increase in the development of tropical patches for the treatment is driving the market growth.
Key Diabetic Neuropathy Drugs Market Challenge
The high cost of treatment is hindering the diabetic neuropathy drugs market growth. The treatment costs of diabetic peripheral neuropathy and its complications can range between $4.6 billion and $13.7 billion in the US annually. As of now, only symptomatic treatment drugs are available for the treatment. The approved drugs for symptomatic treatment are also very few. However, only four branded drugs are available in the market. Such a concentrated market makes it difficult for diabetic neuropathy patients to afford these costly treatments that include overall management of the diabetic neuropathy where drug reimbursement or insurance is difficult. For instance, duloxetine can range from $9.00 to $54.31. Thus, the high cost of drugs used for the treatment of diabetic peripheral neuropathy may hinder the growth of the market during the forecast period.
This diabetic neuropathy drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Parent Market Analysis
Technavio categorizes the diabetic neuropathy drugs market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the diabetic neuropathy drugs market during the forecast period.
Who are the Major Diabetic Neuropathy Drugs Market Vendors?
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
- Alnylam Pharmaceuticals Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Daiichi Sankyo Co. Ltd.
- Eli Lilly and Co.
- Grunenthal GmbH
- Johnson and Johnson Inc.
- NeuroBo Pharmaceuticals Inc.
- Novartis AG
- Pfizer Inc.
This statistical study of the diabetic neuropathy drugs market encompasses successful business strategies deployed by the key vendors. The diabetic neuropathy drugs market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
Product Insights and News
- AstraZeneca Plc - The company offers neuropathy drugs under the brand name of Bydureon.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The diabetic neuropathy drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Diabetic Neuropathy Drugs Market Value Chain Analysis
Our report provides extensive information on the value chain analysis for the diabetic neuropathy drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
- Research and development (R&D) and drug discovery
- Integration and product development
- Manufacturing
- Outbound logistics
- Marketing and sales
- Support services
- Innovation
The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.
Which are the Key Regions for Diabetic Neuropathy Drugs Market?
For more insights on the market share of various regions Request for a FREE sample now!
38% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for the diabetic neuropathy drugs market in North America. Market growth in this region will be faster than the growth of the market in ROW.
The growing prevalence of diabetic neuropathy will facilitate the diabetic neuropathy drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
In 2020, the outbreak of COVID-19 affected all countries in North America, especially the US. It also had a slight negative impact on the diabetic neuropathy drugs market. Some scheduled treatments were either delayed or postponed. Hence, the adoption of diabetic neuropathy drugs declined slightly, which impacted the growth of the regional market in 2020 and Q1 2021 to some extent. However, the imposed restrictions by the half of 2020 may drive the market growth during the forecast period.
What are the Revenue-generating Product Segments in the Diabetic Neuropathy Drugs Market?
To gain further insights on the market contribution of various segments Request for a FREE sample
The diabetic neuropathy drugs market share growth by the calcium channel alpha-2-delta ligand segment will be significant during the forecast period. The calcium channel alpha-2-delta ligand segment includes drugs such as pregabalin (LYRICA), gabapentin (NEURONTIN), valproate sodium (Depacon), and carbamazepine (Tegretol). In December 2004, LYRICA was the second agent to be approved by the US FDA to treat neuropathic pain associated with diabetic peripheral neuropathy. Meanwhile, one alpha-2-delta medication has been licensed by the US Food and Drug Administration (FDA) for the treatment of moderate-to-severe RLS. The segment is expected to experience accelerating growth momentum during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the diabetic neuropathy drugs market size and actionable market insights on post COVID-19 impact on each segment.
You may be interested in:
Diabetic Food market - The market share has the potential to grow by USD 3.76 billion during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 6.24%.
Diabetic Foot Ulcers Therapeutics market - The market share is expected to increase by USD 1.74 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 7.01%.
|
Diabetic Neuropathy Drugs Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2020 |
|
Forecast period |
2021-2025 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 12.20% |
|
Market growth 2021-2025 |
$ 2.37 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
12.57 |
|
Regional analysis |
North America, Europe, Asia, and ROW |
|
Performing market contribution |
North America at 38% |
|
Key consumer countries |
US, Canada, Germany, China, and UK |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Grunenthal GmbH, Johnson and Johnson Inc., NeuroBo Pharmaceuticals Inc., Novartis AG, and Pfizer Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
What are the Key Data Covered in this Diabetic Neuropathy Drugs Market Report?
- CAGR of the market during the forecast period 2021-2025
- Detailed information on factors that will drive diabetic neuropathy drugs market growth during the next five years
- Precise estimation of the diabetic neuropathy drugs market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the diabetic neuropathy drugs industry across North America, Europe, Asia, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of diabetic neuropathy drugs market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch